6,678 trials
Allergic Rhinitis · Urticaria
Primary: Standard Deviation Lateral Position (SDLP) Evaluated During the F1 Simulator Test — -0.041 meters
Gout
Primary: BMI — 33.4 kg/m^2
End Stage Liver Disease · Hepatitis C
Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants
Contact Lens Base Curve (BC) Fit and Comfort
Primary: Correlation Between Subjective CLUE Comfort and Keratometry — 0.042; 0.004; -0.001; -0.002 Pearson Correlation
Myopia · Refractive Error
Primary: Corneal Epithelial Immune Dendritic Cell Density (Central Cornea) — 46.2; 44.8; 62.3 cells/mm2
Brain Disease
Primary: Global Diagnostic Preference Between the Two Exams — 31; 51; 43; 14 participant exams — p=<0.0001
Bipolar Disorder · Alcoholism · Alcohol Dependence
Primary: Amount of Alcohol Consumed — -1.38; -0.69 number of drinks per heavy drinking day
Hyperglycemia · Diabetes Mellitus
Primary: Average Daily Glucose Levels on Days 1-5 After the Initiation of the Treatment Protocol. — 181.8; 173.7; 160.5; 148.4 mg/dL — p=0.35
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
Atherothrombosis
Primary: Changes in Platelet Transcriptome — 77.1 FPKM difference for HBG1 Gene
Ulcerative Colitis
Primary: Percentage of Participants Who Prefer Prefilled Syringe, Smartject™ Device, or Are Undecided (Day of Injections) — 20.9; 76.9; 2.2 Percentage of Participants
Osteoporosis
Primary: Change in Lumbar Spine Areal Bone Mineral Density (BMD) — 0.094; 0.055 gram per square centimeter (g/cm^2) — p=<.0001
Atherosclerosis
Primary: Differential Gene Expression — 77.1 FPKM for HBG1 Gene — p=<0.000005
Opiate-related Disorders
Primary: Hepatic Safety — 278; 318; 41; 62 participants — p=< 0.05
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants Who Correctly Used the Device at the Start of Handling the Device — 55; 49 Participants — p=0.451